论文部分内容阅读
目的探讨肠易激综合征应用复方阿嗪米特治疗临床疗效。方法将2006年1月至2008年12月IBS患者180例,随机分为治疗组90例,对照组90例。观察临床疗效并进行对比。结果治疗组总有效率91.1%,对照组总有效率52.2%,通过统计学分析(P<0.01)差异有统计学意义。结论应用复方阿嗪米特治疗肠易激综合征疗效明显优于单用金双歧三联活菌片,临床上选用复方阿嗪米特肠溶片取得显著疗效,安全有效,使用方便,毒副作用小。
Objective To investigate the clinical efficacy of compound azimit in the treatment of irritable bowel syndrome. Methods 180 patients with IBS from January 2006 to December 2008 were randomly divided into treatment group (90 cases) and control group (90 cases). To observe the clinical efficacy and comparison. Results The total effective rate was 91.1% in the treatment group and 52.2% in the control group. The difference was statistically significant (P <0.01). Conclusion The application of compound azinamamide treatment of irritable bowel syndrome was significantly better than the single use of gold bifidobacterium triple viable tablets clinically selected compound azinamid enteric-coated tablets to obtain a significant effect, safe and effective, easy to use, small side effects.